ResultsIQ

ResultsIQ › Latest results › Nephrocare Health Services Limited

Nephrocare Health Services Limited Q3 FY26 results press release summary

NSE: NEPHROPLUS · BSE: 544647

Results press release of 10 Feb 2026, summarised by AI from the filing.

NephroPlus Q3 FY26 revenue ₹259.7 cr, up 31.7% YoY, with Adj. EBITDA ₹63.1 cr and Adj. PAT ₹34.4 cr.

Key takeaways

  1. Revenue Q3 FY26 revenue ₹259.7 cr, up 31.7% YoY; 9M FY26 revenue ₹733.2 cr, up 36.6% YoY.
  2. Adj. EBITDA Q3 FY26 Adj. EBITDA ₹63.1 cr, up 43.0% YoY; 9M FY26 Adj. EBITDA ₹175.4 cr, up 52.1% YoY.
  3. Adj. PAT Q3 FY26 Adj. PAT ₹34.4 cr, up 71.3% YoY; 9M FY26 Adj. PAT ₹85.9 cr, up 103.3% YoY.
  4. RoCE Annualized RoCE (Pre-Tax) 24.7% FY26 Annualised vs 18.7% FY25, growth of 600 bps.

Original filing on BSE

Nephrocare Health Services Limited Q1 FY27 results

As filed: Revenue ₹282 cr, EBITDA ₹63.9 cr, PAT ₹32.0 cr, EBITDA margin 22.7%.

Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹282 cr). Scored once a year-earlier consolidated quarter exists.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹266 cr, EBITDA ₹53.8 cr, PAT ₹30.4 cr, EBITDA margin 20.2%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹266 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: +11.3% in 30 days (Nifty 500: +3.0%).
  • Q3 FY26: Revenue ₹260 cr, EBITDA ₹60.9 cr, PAT ₹32.2 cr, EBITDA margin 23.4%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹260 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: +4.5% in 30 days (Nifty 500: −7.8%).

Past price moves after results do not indicate future moves. Not a recommendation.

Nephrocare Health Services Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.